COMMUNIQUÉS West-GlobeNewswire

Health Canada grants Nexstim NBS system and NexSpeech® medical device license for Canada
29/03/2019
Company announcement, Helsinki, 29 March 2019 at 9.30 am (EET) Health Canada grants Nexstim NBS system and NexSpeech® medical device license for Canada Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), [...]
Publication of Biohit Oyj Annual Report 2018
29/03/2019
Biohit Oyj Annual Financial Report March 29, 2018 at 9:30 am local time (EET) Biohit Oyj’s Annual Report 2018 is published today in PDF format. The annual report contains financial statements for 2018, the Report of the [...]
Notice of Biohit Oyj’s Annual General Meeting
29/03/2019
Notice of Biohit Oyj’s Annual General Meeting Biohit Oyj Stock Exchange Release March 29, 2019 at 9:30 am local time (EEST) Biohit Oyj shareholders are invited to attend the company’s Annual General Meeting to be held [...]
Laboratory set up in Berlin and strategic collaboration with leading German and Danish cancer coorporative groups entered to develop precision medicine for women’s cancers
29/03/2019
Press release Hoersholm, Denmark and Cambridge, MA, US, March 29, 2019 – Oncology Venture A/S (“OV” or “the Company”) , today announces a new important strategic collaboration to develop precision medicine for women’s [...]
Share capital and voting rights in Orphazyme A/S
29/03/2019
Orphazyme A/S Company announcement No. 11/2019 Company Registration No. 32266355 Copenhagen, March 29, 2019 – Following a share capital increase in Orphazyme A/S (ticker: ORPHA.CO), CVR no. 32266355 (“Orphazyme”) in [...]
Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China
29/03/2019
LONDON, March 29, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a registration-enabling Phase IIb/III study comparing surufatinib (HMPL-012 or sulfatinib) with [...]
IBA sélectionnée pour l’installation d’un centre de protonthérapie à cinq salles à Shenzhen, en Chine
29/03/2019
IBA sélectionnée pour l’installation d’un centre de protonthérapie à cinq salles à Shenzhen, en Chine Les négociations du contrat final débuteront dans les prochaines semaines Louvain-la-Neuve, Belgique, le 29 mars 2019 [...]
IBA Selected to Install Five-room Proton Therapy System in Shenzhen, China
29/03/2019
IBA Selected to Install Five-room Proton Therapy System in Shenzhen, China Final contract negotiations for the public tender will start in the coming weeks Louvain-la-Neuve, Belgium, 29 March, 2019 - IBA ( Ion Beam [...]
IBA VEND DEUX PREMIERS ACCÉLÉRATEURS RHODOTRON® À NORTHSTAR MEDICAL RADIOISOTOPES
29/03/2019
Le contrat signé porte sur huit machines Six autres machines seront livrées dans les prochaines années Louvain-la-Neuve, Belgique, le 29 mars 2019 - IBA (Ion Beam Applications S.A.), le premier fournisseur mondial de [...]
IBA SELLS FIRST TWO RHODOTRON® ACCELERATORS TO NORTHSTAR MEDICAL RADIOISOTOPES
29/03/2019
Total contract signed for eight systems Six others to be delivered over the coming years Louvain-La-Neuve, Belgium, March 29 th , 2019 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton [...]
Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders
29/03/2019
Geneva, Switzerland and Boston, MA – March 29, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]
Genkyotex Reverse Stock Split Takes Effect
29/03/2019
Completion of the 10-for-1 reverse stock split Technical change has no impact on value of shares held by shareholders GKTX ticker on Euronext remains unchanged ARCHAMPS, France, March 29, 2019 (GLOBE NEWSWIRE) -- [...]
Prise d’effet du regroupement d’actions de Genkyotex
29/03/2019
Finalisation du regroupement d’actions par 10 Cet ajustement technique est sans impact sur la valeur des titres Genkyotex détenus par les actionnaires Le code mnémonique reste inchangé (GKTX) ARCHAMPS, France, 29 mars [...]
Innovate Phytotechnologies Inc. (CSE:“INVP”) Conditional Listing Acceptance
29/03/2019
Cannabis Industry Research and Analysis leader to complete Amalgamation with Ross River Minerals Inc. VANCOUVER, British Columbia, March 28, 2019 (GLOBE NEWSWIRE) -- Innovate Phytotechnologies Inc. (“Innovate or The [...]
CrownBio and Hubrecht Organoid Technology Announce a Strategic Partnership, including Exclusive License to Provide Oncology Organoid-Based Preclinical Drug Development and Validation Services
29/03/2019
Partnership combines breakthrough organoid technology with the world’s largest PDX collection to create a unique patient-derived translational research platform SAN DIEGO, March 28, 2019 (GLOBE NEWSWIRE) -- Crown [...]
MedMira Reports 2018 Fourth Quarter and Year End Financial Results
29/03/2019
HALIFAX, Nova Scotia, March 28, 2019 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the financial year ended July 31, 2018. Profit and Loss Highlights Revenue: The [...]
Surgery Partners Announces Pricing of New Note Offering
28/03/2019
NASHVILLE, Tenn., March 28, 2019 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners”) a leading provider of surgical services, today announced that its wholly-owned subsidiary, Surgery Center [...]
GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
28/03/2019
-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile -- Foster City, Calif. and Mechelen, Belgium; March 28, 2019, 22.03 [...]
GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
28/03/2019
-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile -- Foster City, Calif. and Mechelen, Belgium; March 28, 2019, 22.03 [...]

Pages